[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hysteroscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hysteroscopy":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,84,113,135,159,186,210,229,258,280,307],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644570","assessment-of-hysteroscopy-skills-with-a-new-assessment-tool-100644570",false,"NCT07672288","Assessment of Hysteroscopy Skills With a New Assessment Tool","Assessment of Hysteroscopy Skills in an International Multicenter Trial - Gathering Validity Evidence for a Hysteroscopy Assessment Tool","Inclusion Criteria:\n\n* Medical doctors performing hysteroscopy\n* Novices during residency with no experience but permission to operate, and who rely on supervison\n* Experienced doctors with \\> 50 procedures\n* Assessment is done on procedures that are already planned. The evaluation does not change the treament of the patient in any way.\n\nExclusion Criteria:\n\n* Intermediate experienced doctors\n* If complication arrise during the procedure, evaluation is no longer within the scope of the HYSAT tool.","ALL",{"count":18,"type":19},24,"ESTIMATED","OBSERVATIONAL","Objective To investigate validity of the hysteroscopy assessment tool (HYSAT) for assessment of competence in a clinical environment.\n\nMethods Novices and experienced gynecologists are recruited from three hospitals and observed and assessed while performing hysteroscopy. Performances are assessed using the HYSAT tool by two independent raters. Validity evidence is gathered in accordance with Messick's framework: validity evidence for content was ensured in previously published Delphi study, response process is ensured by standardization of written rater instructions. Internal structure is explored using Cronbach's alpha for internal consistency reliability; inter-rater reliability and test-retest reliability are calculated as Pearson's r independently across all ratings. Relationship to other variables is investigated by comparing performances of the participants in each group. Consequences evidence is explored by calculating a pass\u002Ffail standard using the contrasting groups' standard setting method.",[23,24,25,26,27,28],"Hysteroscopy","Assessment Methods in Medical Training","Medical Education","Diagnostic Hysteroscopy","Operative Hysteroscopy","Abnormal Uterine Bleeding",[23,30,24,31,32,33],"Medical education","Gynecology","Training","Assessment evaluation","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":19},"2026-06-22",{"date":42,"type":19},"2026-09-22",{"name":44,"class":45},"Odense University Hospital","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100644453","phase-4-remimazolam-flumazenil-versus-sevoflurane-for-hysteroscopic-day-surgery-100644453","NCT07663877","Remimazolam-Flumazenil Versus Sevoflurane for Hysteroscopic Day Surgery","Remimazolam With Planned Flumazenil Reversal Versus Sevoflurane-based Balanced Anesthesia for Hysteroscopic Day Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female patients aged 20 years or older.\n* Scheduled to undergo ambulatory hysteroscopic surgery under general anesthesia.\n* Able to provide written informed consent.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n\nExclusion Criteria:\n\n* Known hypersensitivity to benzodiazepines, remimazolam, or flumazenil.\n* Chronic use of benzodiazepines or opioids.\n* Severe hepatic dysfunction (Child-Pugh class B or C).\n* Severe renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Epilepsy or other significant neurologic disorders.\n* Pregnancy or breastfeeding.\n* Body mass index (BMI) ≥35 kg\u002Fm².\n* Severe obstructive sleep apnea.\n* Uncontrolled serious systemic disease that may preclude ambulatory surgery.\n* Refusal or inability to provide informed consent.","FEMALE","20 Years",{"count":57,"type":19},124,"INTERVENTIONAL",[60],"PHASE4","This prospective, single-center, randomized controlled trial aims to compare remimazolam anesthesia with planned flumazenil reversal and sevoflurane-based balanced anesthesia in adult women undergoing ambulatory hysteroscopic surgery.\n\nParticipants will be randomly assigned in a 1:1 ratio to receive either remimazolam for induction and maintenance followed by flumazenil reversal or propofol induction followed by sevoflurane-based balanced anesthesia. The primary outcome is anesthesia-controlled time, defined as the sum of induction time and emergence time. Secondary outcomes include recovery profiles, postoperative symptoms, quality of recovery, hemodynamic stability, and the incidence of re-sedation. The study will evaluate whether a remimazolam-flumazenil strategy can improve operating room efficiency while maintaining recovery quality and safety comparable to conventional sevoflurane-based anesthesia in the ambulatory surgery setting.",[23,63,64],"Ambulatory Surgery","General Anesthesia",[66,67,68,69,70,71,72,73,74],"remimazolam","flumazenil","sevoflurane","ambulatory surgery","day surgery","hysteroscopy","general anesthesia","recovery profile","anesthesia controlled time","2026-06-17",{"date":35,"type":38},{"date":78,"type":19},"2026-06",{"date":80,"type":19},"2028-06",{"name":82,"class":45},"Chung-Ang University Gwangmyeong Hospital",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":96,"studyType":20,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100640629","fertility-outcomes-after-antibiotic-treatment-in-women-with-chronic-endometritis-100640629","NCT07603492","Fertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis","Monitoring of Reproductive Outcomes in Women With Chronic Endometritis: A Prospective Cohort Study on the Impact of Antibiotic Treatment on Fertility and Obstetric Outcomes","MORE","Inclusion Criteria\n\n* Female participants aged 18-40 years.\n* Diagnosis of infertility (primary or secondary infertility).\n* Indication for diagnostic hysteroscopy with endometrial biopsy as part of infertility evaluation.\n* Suspected or confirmed chronic endometritis.\n* Ability and willingness to provide written informed consent prior to any study-related procedures.\n* Willingness to undergo protocol-defined antibiotic treatment.\n* Willingness to comply with study procedures and follow-up assessments.\n* Agreement to reproductive outcome monitoring following treatment, including spontaneous conception and pregnancies achieved through assisted reproductive technologies (ART).\n\nExclusion Criteria\n\n* Age \\>40 years.\n* Current pregnancy.\n* Known hypersensitivity or contraindication to tetracycline antibiotics or other study-related antibiotic therapy without a suitable alternative treatment option.\n* Severe systemic disease or medical condition that, in the opinion of the investigator, could interfere with study participation, safety, or interpretation of study results.\n* Active malignant disease requiring systemic treatment.\n* HIV infection or other severe immunodeficiency disorder.\n* Acute pelvic inflammatory disease or clinically significant active genital tract infection requiring immediate treatment.\n* Previous participation in this study.\n* Inability to undergo planned hysteroscopy or endometrial biopsy.\n* Inability or unwillingness to comply with study procedures or follow-up requirements.\n* Failure or refusal to provide written informed consent.","18 Years","40 Years",{"count":95,"type":19},100,"2 Years","Chronic endometritis (CE) is a long-lasting inflammation of the lining of the uterus. Many women with CE do not have symptoms, but the condition may affect fertility, embryo implantation, and pregnancy outcomes. CE is usually diagnosed during hysteroscopy, a procedure that allows doctors to look inside the uterus and collect a small tissue sample for laboratory testing.\n\nThe goal of this prospective cohort study is to learn how common CE is in women with infertility and to determine whether antibiotic treatment improves reproductive outcomes. The study will also examine whether hysteroscopic findings match laboratory-confirmed CE and whether certain findings can help doctors diagnose CE more accurately. In addition, researchers will study the types of bacteria found in the uterine lining and their possible relationship to fertility and pregnancy outcomes.\n\nThe main questions the study aims to answer are:\n\n* How common is chronic endometritis in women undergoing infertility evaluation?\n* Does antibiotic treatment improve fertility and pregnancy outcomes in women with CE?\n* Can hysteroscopic findings reliably predict CE confirmed by laboratory testing?\n* Are specific bacteria associated with poorer reproductive outcomes? Researchers will enroll approximately 100 women aged 18 to 40 years with diagnosed infertility who are scheduled for hysteroscopy and endometrial biopsy as part of infertility evaluation. Participants with severe systemic disease, pregnancy, inability to undergo hysteroscopy or antibiotic treatment, or allergy to study antibiotics without a suitable alternative will not be included.\n\nParticipants will:\n\n* Undergo diagnostic hysteroscopy and endometrial biopsy\n* Have tissue samples examined using histopathology and immunohistochemistry to identify CE\n* Receive standardized antibiotic treatment if CE is confirmed\n* Be followed for up to 12 months after treatment to monitor fertility outcomes\n* Continue follow-up during pregnancy, if pregnancy occurs, to assess pregnancy and delivery outcomes Researchers will evaluate spontaneous pregnancies, embryo transfer success, implantation rates, miscarriage rates, time to pregnancy, and live birth outcomes. Pregnancy complications such as preeclampsia, placental disorders, premature rupture of membranes, and preterm birth will also be recorded.\n\nThe study is expected to run from January 2026 through December 2029. Data collected during the study may help improve the diagnosis and treatment of chronic endometritis in women with infertility and may support better reproductive outcomes in clinical practice.",[99,100,23,101],"Endometritis","Infertility","Pregnancy Disease","RECRUITING","2026-05-22",{"date":105,"type":38},"2026-05-27",{"date":107,"type":38},"2026-01-01",{"date":109,"type":19},"2030-01-01",{"name":111,"class":112},"Faculty Hospital Kralovske Vinohrady","OTHER_GOV",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":93,"enrollmentInfo":120,"targetDuration":4,"studyType":58,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":83},"100618005","verbal-analgesia-versus-standard-care-for-pain-control-in-women-with-primary-infertility-undergoing-office-hysteroscopy-100618005","NCT07325994","Verbal Analgesia Versus Standard Care for Pain Control in Women With Primary Infertility Undergoing Office Hysteroscopy","Verbal Analgesia Versus Standard Care for Pain Control in Women With Primary Infertility Undergoing Vaginoscopic Office Hysteroscopy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* o Women aged 18-40 years.\n\n  * Diagnosis of primary infertility (failure to conceive after ≥12 months of unprotected intercourse).\n  * Indication for diagnostic office hysteroscopy.\n  * Regular menstrual cycles.\n\nExclusion Criteria:\n\n* o Secondary infertility.\n\n  * Known pelvic infection, cervicitis, or vaginitis.\n  * Use of analgesics within 8 hours prior to procedure.\n  * Cervical stenosis, prior failed hysteroscopy, or known uterine anomaly.\n  * Contraindication to NSAIDs\n  * Pregnancy or suspected pregnancy.",{"count":121,"type":19},92,[123],"NA","Office hysteroscopy is a cornerstone in the diagnostic evaluation of infertile women, enabling direct visualization of the uterine cavity for identifying intrauterine pathology. The vaginoscopic (\"no-touch\") approach, which eliminates the use of a speculum and tenaculum, is increasingly adopted due to improved tolerability, higher success rates, and reduced pain compared to conventional methods.",[23],"2026-01-03",{"date":128,"type":38},"2026-01-08",{"date":130,"type":38},"2025-10-20",{"date":132,"type":19},"2026-03-15",{"name":134,"class":45},"Cairo University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":58,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100606259","use-of-vr-for-diagnostic-hysteroscopy-100606259","NCT07173231","Use of VR for Diagnostic Hysteroscopy","Comparisons Between Virtual Reality and Hypno-Virtual Reality for Procedural Pain and Anxiety During a Diagnostic Hysteroscopy: A Pilot Randomized Controlled Trial","VR-HYSTERO","Inclusion Criteria:\n\n* Minimum 18 years old\n* Speak and read French or English\n* Scheduled to undergo a diagnostic hysteroscopy\n\nExclusion Criteria:\n\n* Having a diagnosis of epilepsy\n* Recent ophthalmologic surgery (\\\u003C 1month) or any ophtalmologic problems that could interfere with the patient's ability to use the VR technology",{"count":144,"type":19},45,[123],"Background: Hysteroscopy (HSC) is a minimally invasive gynecological procedure that is considered to be the gold standard for diagnosing and treating intrauterine pathologies. In recent years, its use in outpatient settings for diagnosis has grown significantly due to its efficiency, low complication rate, and good patient acceptability. However, many patients still report significant pain and anxiety during the procedure. Despite advances in instrumentation and technique, pain remains a key reason for procedural failure, often worsened by preprocedural anxiety. While pharmacological strategies can be used to address this issue, they are not always suitable due to lack of effectiveness or feasibility. As a result, non-pharmacological approaches such as virtual reality (VR) and hypnosis are being increasingly explored. VR has shown potential in reducing pain and anxiety during medical procedures, and its combination with hypnosis may offer enhanced benefits, though current evidence is limited.\n\nObjective: This pilot study aims to assess the effectiveness of immersive virtual reality (IVR) and Hypno-VR (HVR) in managing pain and anxiety during diagnostic HSC and to evaluate the feasibility and acceptability of both IVR and HVR interventions in an outpatient clinical setting.\n\nMethods: This pilot randomized controlled trial (RCT) will follow a three-arm parallel design to compare: 1- standard care, 2- IVR + standard care, and 3- HVR + standard care, during diagnostic HSC. A total of 45 participants (15\u002Farm) will be recruited from the CHU Sainte-Justine's gynecology clinic and randomly assigned to one of the three groups. Primary outcomes will concern feasibility and acceptability including satisfaction of both patients and healthcare professionals. Secondary outcomes will assess self-reported pain and anxiety, physiological responses, procedure duration, procedure failure, and conversion rate from the \"no-touch\" vaginoscopy technique to traditional tools like the speculum and tenaculum. Demographic characteristics will also be explored as potential moderators of intervention effectiveness.\n\nResults\u002FConclusion: This pilot study will provide preliminary data on the effects of IVR and HVR on procedural pain and anxiety during diagnostic HSC. It will also assess the feasibility and the acceptability of integrating these interventions into an outpatient setting. The findings will provide essential data in preparation for a larger clinical trial",[23,148,149],"Anxiety","Pain","2025-09-08",{"date":152,"type":38},"2025-09-15",{"date":154,"type":19},"2025-11",{"date":156,"type":19},"2026-03",{"name":158,"class":45},"St. Justine's Hospital",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":58,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":83},"100573369","phase-4-magnesium-and-cramping-100573369","NCT06745388","Magnesium and Cramping","Evaluating the Impacts of Intravenous Magnesium Sulfate and Ketamine on Cramping Pain and Total Opioid Consumption Following Hysteroscopy: A Prospective, Randomized Trial","Inclusion Criteria:\n\n* Patients undergoing an elective hysteroscopy or dilation and curettage (D\\&C)\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Chronic Pain Patients (taking opioids within one week of procedure)\n* Psychiatric Disorders (current treatment for anxiety\u002Fdepression)\n* Allergies to any of the medications that will be administered\n* Current use of magnesium, analgesics, antidepressants, anxiolytics, or opioids\n* ASA Physical Status 4 or above\n* Developmentally delayed patients that would not be able to verbalize pain scores\n* Minors (under 18 years of age)\n* Pregnant women",{"count":167,"type":19},150,[60],"Hysteroscopy (an exam to look inside the uterus) is one of the most frequently performed procedures for patients with cervical or uterine disorders. It is the gold standard for evaluating various intrauterine problems, pre-menopausal and post-menopausal abnormal uterine bleeding, as well as being a vital examination modality for infertility work-up. Although hysteroscopy is a minimally invasive procedure, it is still known to be a painful experience that requires effective analgesia (meaning pain reduction) to achieve maximum patient comfort and cooperation. Historically, opioids, particularly fentanyl, have held precedence as the primary agents for providing analgesia following surgery of this type. However, despite their efficacy, these agents come with notable drawbacks, including the potential for serious side effects such as respiratory depression, addiction, and postoperative nausea and vomiting.\n\nBoth magnesium and ketamine are routinely used to reduce pain following this procedure. Both drugs work on the N-methyl-D-aspartate (NMDA) receptor in the brain to reduce pain, and magnesium has an additional effect in that it can relax smooth muscles. Magnesium has been used successfully to reduce the pain associated with menstrual cramps, which is similar to the pain patients experience after hysteroscopy.\n\nA recent study demonstrated the benefits of adding intravenous magnesium with routine anesthesia during hysteroscopy, revealing a significant decrease in postoperative pain and rescue analgesics. However, this study did not compare the effects of magnesium to ketamine, nor did they characterize the nature of the patients' pain. It is unclear if the pain reduction with magnesium comes from its effect on the NMDA receptor or from it's cramp-reduction effect. We seek to establish whether administering IV magnesium, compared to ketamine, can specifically mitigate uterine cramping pain and total opioid consumption in hopes of finding additional safe and effective pain modalities for patients.\n\nThis is a prospective, randomized trial enrolling participants undergoing an elective hysteroscopy or Dilation and Curettage (D\\&C) at Corewell Health William Beaumont University Hospital in Royal Oak. Participants will be randomized to 1 of 3 treatments: Intravenous (IV) Magnesium, IV Push Ketamine, or Placebo. Opioid consumption is recorded via the electronic medical record (EMR), while overall pain and cramping pain will be captured post-procedure in the hospital and 24 hours later via a phone call.",[171,172,23],"Uterine Cramps","Postoperative Pain Management",[71,174,175,176],"magnesium sulfate","cramping","ketamine","2025-08-15",{"date":179,"type":38},"2025-08-20",{"date":181,"type":38},"2025-07-29",{"date":183,"type":19},"2026-09",{"name":185,"class":45},"Corewell Health East",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":58,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":83},"100565448","bladder-distension-for-pain-relief-in-patients-with-excessive-anteflexion-of-uterus-undergoing-office-hysteroscopy-100565448","NCT06642311","Bladder Distension for Pain Relief in Patients With Excessive Anteflexion of Uterus Undergoing Office Hysteroscopy","Bladder Distension for Pain Relief in Patients With Excessive Anteflexion of Uterus Undergoing Office Hysteroscopy: a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with excessive anteflexion of the uterus\n\nExclusion Criteria:\n\n* Cervical pathology\n* Previous cervical surgery\n* Severe vaginal bleeding","60 Years",{"count":195,"type":19},48,[123],"This study is conducted to assess whether the passive uterine straightening of the uterus by means of bladder filling is associated with less pain experienced by patients with excessive anteflexion of the uterus during office hysteroscopy.",[23],[200,149,201],"Full bladder","Excessive anteflexion of the uterus","2025-04-25",{"date":204,"type":38},"2025-04-29",{"date":206,"type":38},"2024-10-30",{"date":208,"type":19},"2025-04-30",{"name":134,"class":45},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":58,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":227,"leadSponsor":228,"locationsCount":46},"100565048","ultrasound-guidance-of-office-hysteroscopy-in-patients-with-history-of-failure-of-office-hysteroscopy-due-to-cervical-stenosis-100565048","NCT06637111","Ultrasound Guidance of Office Hysteroscopy in Patients With History of Failure of Office Hysteroscopy Due to Cervical Stenosis.","Ultrasound Guidance of Office Hysteroscopy in Patients With History of Failure of Office Hysteroscopy Due to Cervical Stenosis.A Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with history of failure of office hysteroscopy\n\nExclusion Criteria:\n\n* Pelvic inflammatory disease\n* Severe vaginal bleeding\n* Pregnancy\n* Allergy to lidocaine, prilocaine or diclofenac potassium","65 Years",{"count":219,"type":19},58,[123],"The study is conducted to assess whether ultrasound guidance can facilitate the access of the office hysteroscope into the uterine cavity of patients with previous failure of office hysteroscopy due to cervical stenosis.",[23],[23,224,149],"Ultrasound",{"date":208,"type":38},{"date":206,"type":38},{"date":208,"type":19},{"name":134,"class":45},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":58,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":83},"100530524","the-effects-of-remimazolam-on-the-incidence-of-severe-hypoxia-during-sedated-hysteroscopy-for-assisted-reproduction-in-overweight-or-obese-patients-100530524","NCT06187896","The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients","The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients: a Randomized, Controlled Clinical Trial","RP","Inclusion Criteria:\n\n1. Age between 20 and 50 years.\n2. Patients undergoing sedated hysteroscopy for assisted reproduction.\n3. ASA classification I-II.\n4. BMI ≥ 23 kg\u002F㎡.\n5. Patients who have signed an informed consent form.\n\nExclusion Criteria:\n\n1. SpO2 \\\u003C 95% in patients inhaling air upon entering the room.\n2. Diagnosed with chronic obstructive pulmonary disease (COPD) or currently suffering from other acute and chronic lung diseases requiring long-term or intermittent oxygen therapy.\n3. Patients with a history of mental and neurological disorders: such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, etc.\n4. Patients with severe liver dysfunction.\n5. Patients with severe renal insufficiency (requiring dialysis before surgery).\n6. Severe heart failure (METS \\\u003C 4).\n7. History of drug abuse and\u002For alcohol abuse within the 2 years preceding the screening period (consuming more than three times the standard alcoholic beverages daily, approximately 10g of alcohol, or equivalent to 50g of Chinese alcohol).\n8. Allergies or contraindications to benzodiazepines, flumazenil, opiates and their rescue medications, propofol, eggs, or soy products.\n9. Breastfeeding women.\n10. Patients whom investigator believe are unsuitable for participating in this trial.","50 Years",{"count":239,"type":19},600,[123],"Hypoxia is a common adverse event during sedated hysteroscopy for assisted reproduction, and it is more likely to occur in overweight or obese patients. In sedated gastroscopy, the incidence of hypoxia with remimazolam is lower than that with propofol. The present study is a single-center, randomized, single-blind, controlled clinical trial. Overweight or obese patients undergoing sedated hysteroscopy for diagnosis and treatment, with ASA grade I or II, were selected as subjects and randomly divided into an experimental group and a control group, with 300 subjects in each group. Sedation induction and maintenance are performed using remimazolam or propofol combined with remifentanil, respectively, to compare the incidence of severe hypoxia during surgery between the two groups of patients.",[243,23,244],"Hypoxia","Overweight or Obesity",[246,247,66,248],"hypoxia","sedated hysteroscopy","propofol","2024-09-12",{"date":251,"type":38},"2024-09-19",{"date":253,"type":38},"2024-01-01",{"date":255,"type":19},"2026-04",{"name":257,"class":45},"RenJi Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":58,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":83},"100558995","bladder-distension-for-pain-relief-in-nullliparous-patients-undergoing-diagnostic-office-hysteroscopy-100558995","NCT06558370","Bladder Distension for Pain Relief in Nullliparous Patients Undergoing Diagnostic Office Hysteroscopy","Bladder Filling for Pain Relief in Nullliparous Patients Undergoing Diagnostic Office Hysteroscopy","Inclusion Criteria:\n\n* Nulliparity\n\nExclusion Criteria:\n\n* Parous patients\n* Cervical pathology\n* Previous cervical surgery\n* Severe vaginal bleeding.","48 Years",{"count":267,"type":19},114,[123],"This study is conducted to assess whether the passive uterine straightening of the uterus by means of bladder filling is associated with less pain experienced by nulliparous women during office hysteroscopy.",[23],[23,200,149],"2024-08-16",{"date":274,"type":38},"2024-08-19",{"date":276,"type":19},"2024-10-15",{"date":278,"type":19},"2025-06-15",{"name":134,"class":45},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":54,"minAge":92,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":58,"phases":290,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100552892","hysteroscopic-suture-fixation-of-mirena-in-the-treatment-of-adenomyosis-100552892","NCT06478992","Hysteroscopic Suture Fixation of Mirena in the Treatment of Adenomyosis","A Multicenter Randomized Controlled Trial of Hysteroscopic Suture Fixation of Mirena in the Treatment of Adenomyosis","Inclusion Criteria:\n\n* Pain due to adenomyosis (lower abdominal pain and low back pain) visual analogue scale (VAS) ≥40mm or menstrual volume score (PBAC) ≥100;\n\n  * Adenomyosis was confirmed by ultrasound or magnetic resonance imaging (MRI);\n\n    * The uterine volume measured by transvaginal gynecological three-dimensional ultrasound was more than 150cm3 and less than 280cm3 (the volume was about 280cm3 at 10 weeks of pregnancy); ④ A strong desire to preserve the uterus; ⑤ No fertility requirements within nearly one year;\n\n      * Premenopausal women aged ≥18 years old; ⑦ Willing and able to abide by the study protocol, and have the ability to clearly judge the amount of menstruation and the degree of pain.\n\nExclusion Criteria:\n\n* Presence of contraindications to Mirena (known or suspected pregnancy, current pelvic inflammatory disease or recurrent pelvic inflammatory disease, lower genital tract infection, postpartum endometritis, infectious abortion within the past 3 months, cervicitis, cervical dysplasia, uterine or cervical malignant lesions, progestin-dependent tumors, abnormal uterine bleeding of unknown cause, congenital or acquired uterine abnormalities, these include fibroids that deform the cervix, conditions that increase susceptibility to infections, acute liver diseases or tumours, allergy to active ingredients or excipient);\n\n  * Malignant tumors (including reproductive system and other systems);\n\n    * Acute stage of heart, liver and kidney failure or other patients who cannot tolerate operation;\n\n      * The history of Mirena displacement or expulsion;\n\n        * Ultrasound showed the presence of ovarian chocolate cyst; ⑥ The presence of deep endometrial nodules by gynecological examination;\n\n          * The presence of intramural or subserous myoma ≥3cm or any size of uterine submucosal myoma (type 0, 1, 2); ⑧ Patients who are unwilling to participate in the study or who were considered by the investigators to be unsuitable for the study.","55 Years",{"count":289,"type":19},144,[123],"The purpose of this study was to evaluate the efficacy and safety of hysteroscopic Mirena fixation in patients with adenomyosis with enlarged uterus, compared with simple Mirena placement under hysteroscopy. Whether the curative effect is not inferior to and reduces the incidence of Mirena expulsion.",[293,23],"Adenomyosis",[295,296,297,293],"Suture fixation","Expulsion","Mirena","2024-06-23",{"date":300,"type":38},"2024-06-27",{"date":302,"type":19},"2024-06-30",{"date":304,"type":19},"2026-06-30",{"name":306,"class":45},"First People's Hospital of Hangzhou",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":315,"sex":54,"minAge":92,"maxAge":93,"enrollmentInfo":316,"targetDuration":96,"studyType":20,"phases":4,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":4},"100505251","hysteroscopic-evaluation-and-the-clinical-outcomes-of-vaginal-repair-of-cesarean-section-scar-defects-100505251","NCT05858931","Hysteroscopic Evaluation and the Clinical Outcomes of Vaginal Repair of Cesarean Section Scar Defects","Association Between Hysteroscopic Evaluation and the Clinical Outcomes of Vaginal Repair of Cesarean Section Scar Defects","CSD","Inclusion Criteria:\n\n* The inclusion criteria are non-pregnant patients who had one or more cesarean sections, patients who had intermenstrual spotting after the cesarean section or those in which the TRM was less than 3.0 mm at the preoperative stage, and patients who underwent MRI and TVS to evaluate the size of the defect and the TRM before surgery\n\nExclusion Criteria:\n\n* Patients who had a history of chronic diseases (such as cerebro-cardiovascular diseases, malignancies and diabetes mellitus), endocrine disorders, menstrual irregularities before cesarean section, coagulation disorders, use of intrauterine devices, sub-mucous myoma, endometrial diseases, endometrial cysts, uterine fibroids, and adenomyosis after cesarean section",true,{"count":95,"type":19},"Cesarean section scar defects (CSDs) are one of the long-term complications following cesarean section. They can be detected by transvaginal sonography, hysterosalpingography, sonohysterography and magnetic resonance imaging (MRI). Hysteroscopy is frequently used in evaluating endometrial disease. However, the description of CSDs by hysteroscopy is very limited. Only a few papers about hysteroscopy evaluation have been published. This is an exploratory study to compare hysteroscopic findings with the clinical outcomes of vaginal repair of CSDs.",[319,23],"Magnetic Resonance Imaging",[321,71,322],"cesarean section scar defect","surgical outcomes","2024-04-21",{"date":325,"type":38},"2024-04-23",{"date":327,"type":19},"2024-06-01",{"date":329,"type":19},"2027-12-31",{"name":331,"class":45},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine"]